Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > U.S. Nuclear Medicine Market

U.S. Nuclear Medicine Market Share

Report ID: GMI11978
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

U.S. Nuclear Medicine Market Share

The market is dominated by some of the major market players. The market is competitive in nature, with major organizations, local small players, and start-ups joining the industry competition. The key industry players are consistently involved in creating new opportunities in the healthcare sector. Leading companies, such as Jubilant Pharma, Cardinal Health, Inc., Novartis AG, Lantheus, GE Healthcare, and Boston Scientific Corporation among others maintain a strong presence with extensive product portfolios of nuclear medicine, diagnostic products, and therapeutic products, technological innovations, and global market reach.

U.S. Nuclear Medicine Market Companies

Some of the eminent market participants operating in the U.S. nuclear medicine industry include:

Actinium Pharmaceuticals
Best Medical International
Boston Scientific Corporation
Bracco
Cardinal Health
Curium Pharma
GE Healthcare
GT Medical Technologies
Iso-Tex Diagnostics
ITM Isotope Technologies
Jubilant Pharma
Lantheus
Novartis
RadioMedix
RLS Radiopharmacies
Siemens Healthineers
Sirtex
Sun Pharmaceutical Industries
Theragenics Corporation

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. nuclear medicine industry was valued at approximately USD 6.5 billion in 2023 and is expected to grow at a 15.6% CAGR from 2024 to 2032, driven by technological advancements and a growing focus on personalized medicine.

The diagnostics segment dominated the market with a revenue of around USD 4.5 billion in 2023, fueled by the increasing prevalence of chronic diseases and advancements in imaging technologies.

East North Central nuclear medicine market accounted for USD 1 billion in revenue in 2023 and is anticipated to grow at a 16% CAGR between 2024 and 2032, driven by the rising prevalence of cancer and cardiovascular diseases in states like Illinois and Michigan.

Key players in the U.S. nuclear medicine industry include Actinium Pharmaceuticals, Best Medical International, Boston Scientific Corporation, Bracco, Cardinal Health, Curium Pharma, GE Healthcare, and GT Medical Technologies.